Micvotabart pelidotin (MICVO)
Various Solid Tumors
Key Facts
About Pyxis Oncology
Pyxis Oncology is a public, clinical-stage biotech company dedicated to transforming cancer treatment through a differentiated portfolio of ADCs and immunotherapies. Its innovative approach targets tumor cells and the immunosuppressive tumor microenvironment, with a lead program, MICVO, showing promise in Phase 1 trials for head and neck cancer. The company is led by an experienced management team with a track record in oncology drug development and company building, and is strategically advancing its pipeline both as monotherapies and in combination with established agents like pembrolizumab.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Individualized mRNA Cancer Immunotherapies | BioNTech | Phase 2/3 |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved |
| IMA30X Series (ACTengine®) | Immatics | Pre-clinical |
| RP2 / RP2 + nivolumab | Replimune | Phase 1 |
| Bicycle Toxin Conjugates (BTCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Bicycle Radio Conjugates (BRCs) | Bicycle Therapeutics | Preclinical/Discovery |
| OST-tADC Platform | OS Therapies | Pre-clinical |